Bristol Myers Squibb, Acceleron announce EC approves Reblozyl to treat transfusion?dependent anemia in adult with MDS or beta thalassemia

Bristol Myers Squibb and Acceleron Pharma Inc. announced that the European Commission (EC) has approved Reblozyl (luspatercept) for the treatment of: Adult patients with transfusion─dependent anemia due to very low─, low─ and intermediate─risk myelodysplastic syndromes (MDS) with ring sideroblasts